2019
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas
Foss FM, Horwitz SM, Civallero M, Bellei M, Marcheselli L, Kim WS, Cabrera ME, Dlouhy I, Nagler A, Advani RH, Pesce EA, Ko Y, Montoto S, Chiattone C, Moskowitz A, Spina M, Cesaretti M, Biasoli I, Federico M. Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. American Journal Of Hematology 2019, 95: 151-155. PMID: 31709579, PMCID: PMC8025136, DOI: 10.1002/ajh.25674.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overDisease-Free SurvivalEnteropathy-Associated T-Cell LymphomaFemaleHematopoietic Stem Cell TransplantationHumansIncidenceLymphoma, T-Cell, PeripheralMaleMiddle AgedNeoplasm ProteinsReceptors, Antigen, T-Cell, gamma-deltaSurvival RateTransplantation, AutologousConceptsHepatosplenic T-cell lymphomaT-cell lymphomaEnteropathy-Associated T-Cell LymphomaGamma-delta T-cell lymphomaT-cell ProjectStem cell transplantationCell lymphomaRare subtypeFirst remissionTreatment patternsCell transplantationAutologous stem cell transplantationAllogeneic stem cell transplantationFirst-line therapyLarge prospective trialsProgression-free survivalCells projectRare T cellsNovel treatment approachesFree survivalLine therapyOverall survivalProspective trialAnthracycline regimensClinical trials
2007
Cutaneous T-cell lymphoma: Biologic targets for therapy
Choi J, Foss F. Cutaneous T-cell lymphoma: Biologic targets for therapy. Current Hematologic Malignancy Reports 2007, 2: 272-277. PMID: 20425380, DOI: 10.1007/s11899-007-0037-8.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsApoptosisCD4 AntigensClinical Trials as TopicDiphtheria ToxinDrug Delivery SystemsDrug DesignEpigenesis, GeneticGene Expression Regulation, NeoplasticHumansImmunologic FactorsImmunotherapyInterferon-gammaInterleukin-2Lymphoma, T-Cell, CutaneousNeoplasm ProteinsPhotopheresisRecombinant Fusion ProteinsSkin NeoplasmsT-Lymphocyte SubsetsTumor EscapeConceptsCutaneous T-cell lymphomaReceptor-dependent signaling pathwaysEpigenetic changesSignaling pathwaysClonal populationsSkin-homing lymphocytesT-cell lymphomaT cell activationPersistence of tumorHost immune systemCTCL cellsCancer immunosurveillanceImmune cellsLangerhans cellsCytotoxic phenotypeDisease pathogenesisBiologic targetsImmune systemCellsTherapyDiseasePhenotypePathwayImmunosurveillanceActivation
2003
Interleukin-2 receptor–directed therapies for cutaneous lymphomas
Foss FM, Waldmann TA. Interleukin-2 receptor–directed therapies for cutaneous lymphomas. Hematology/Oncology Clinics Of North America 2003, 17: 1449-1458. PMID: 14710895, DOI: 10.1016/s0889-8588(03)00110-2.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalClinical Trials as TopicDiphtheria ToxinDrug Delivery SystemsGene Expression Regulation, NeoplasticHumansImmunoconjugatesImmunotherapyImmunotoxinsInterleukin-2Lymphoma, T-Cell, CutaneousNeoplasm ProteinsProtein IsoformsProtein SubunitsReceptors, Interleukin-2Recombinant Fusion ProteinsRetinoidsSkin NeoplasmsConceptsT-cell lymphomaIL-2RIL-2/IL-2R systemPeripheral T-cell lymphomaAnaplastic large cell lymphomaNatural killer lymphomaReceptor-directed therapyIL-2R systemIL-2 receptorLarge cell lymphomaRational therapeutic strategiesIL-2R subunitsCutaneous lymphomasSpecific immunotherapyIL-2Cell lymphomaTherapeutic strategiesLymphomaHumanized antibodyCTCLBeta-emitting radionuclidesAntibodiesImmunotherapyTherapyAgents